March 5, 2021March 5, 2021
Keytruda Will No Longer Treat Advanced Small Cell Lung Cancers in US
News
After failing to significantly extend survival in a confirmatory Phase 3 trial, Keytruda (pembrolizumab) will no longer be available in the ... Read more
March 3, 2021March 3, 2021
Ilixadencel-Sutent Combo Shows ‘Meaningful’ Survival in Advanced Kidney Cancer Patients
News
A combination of ilixadencel plus first-line treatment with Sutent (sunitinib) prolonged overall survival to a clinically meaningful extent in newly diagnosed ... Read more
March 1, 2021March 1, 2021
Imfinzi No Longer Available in US for Advanced Bladder Cancer
News
After consulting with the U.S. Food and Drug Administration (FDA), AstraZeneca has announced that Imfinzi (durvalumab) — which last year ... Read more
February 26, 2021February 26, 2021
Trial Will Test AFM24-Tecentriq Combo for EGFR-positive Advanced Cancers
News
Affimed will team up with Roche to conduct a Phase 1/2a clinical trial investigating its innate cell engager AFM24 — ... Read more
February 24, 2021February 24, 2021
Tebentafusp Named FDA Breakthrough Therapy for Advanced Eye Cancer
News
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Immunocore‘s tebentafusp (IMCgp100) for HLA-A2 positive, inoperable, or ... Read more
February 22, 2021February 22, 2021
Keytruda-Lenvima Combo Better Than Sutent in Treating Kidney Cancer
News
A combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) worked better than standard Sutent (sunitinib) at delaying disease progression and prolonging ... Read more
February 19, 2021February 19, 2021
Opdivo Effective as Bladder Cancer Post-surgery Therapy, Data Show
News
Treatment with Opdivo (nivolumab) after surgery significantly delays disease recurrence or death in patients with muscle-invasive urothelial carcinoma, a form ... Read more
February 17, 2021February 17, 2021
FLX475 Shows Promising Safety, Anti-Tumor Activity; Trial Recruiting
News
FLX475, an investigational anti-cancer therapy by RAPT Therapeutics, is safe and shows promising anti-tumor clinical activity, both alone and in ... Read more
February 15, 2021February 15, 2021
Biond and Sanofi Partner, Plan for Trial of Checkpoint Inhibitor BND-22
News
Biond Biologics and Sanofi have entered into a worldwide licensing agreement to advance BND-22, a novel immune checkpoint inhibitor, into ... Read more
February 12, 2021February 12, 2021
FDA Approves Libtayo, 1st Immunotherapy for Advanced Basal Cell Carcinoma
News
The U.S. Food and Drug Administration (FDA) has approved Libtayo (cemiplimab-rwlc), making it the first immunotherapy for people with advanced ... Read more
February 10, 2021February 10, 2021
CAR T-cell Therapy Breyanzi Approved for Large B-cell Lymphomas
News
The U.S. Food and Drug Administration (FDA) has approved the CAR T-cell therapy Breyanzi (lisocabtagene maraleucel) for treating adults with ... Read more
February 8, 2021February 8, 2021
Keytruda-Yervoy Combo of No Benefit in Advanced NSCLC, Trial Data Show
News
First-line treatment with a combination of Yervoy (ipilimumab) and Keytruda (pembrolizumab) failed to prolong survival and delay disease progression in ... Read more

March 5, 2021March 5, 2021

Keytruda Will No Longer Treat Advanced Small Cell Lung Cancers in US

News

After failing to significantly extend survival in a confirmatory Phase 3 trial, Keytruda (pembrolizumab) will no longer be available in the U.S. for people with previously treated metastatic small cell lung ... Read more

March 3, 2021March 3, 2021

Ilixadencel-Sutent Combo Shows ‘Meaningful’ Survival in Advanced Kidney Cancer Patients

News

A combination of ilixadencel plus first-line treatment with Sutent (sunitinib) prolonged overall survival to a clinically meaningful extent in newly diagnosed patients with metastatic renal cell carcinoma (mRCC), a form of ... Read more

March 1, 2021March 1, 2021

Imfinzi No Longer Available in US for Advanced Bladder Cancer

News

After consulting with the U.S. Food and Drug Administration (FDA), AstraZeneca has announced that Imfinzi (durvalumab) — which last year failed a confirmatory Phase 3 trial — will no longer ... Read more

February 26, 2021February 26, 2021

Trial Will Test AFM24-Tecentriq Combo for EGFR-positive Advanced Cancers

News

Affimed will team up with Roche to conduct a Phase 1/2a clinical trial investigating its innate cell engager AFM24 — a form of immunotherapy — in combination with Tecentriq (atezolizumab) ... Read more

February 24, 2021February 24, 2021

Tebentafusp Named FDA Breakthrough Therapy for Advanced Eye Cancer

News

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Immunocore‘s tebentafusp (IMCgp100) for HLA-A2 positive, inoperable, or advanced uveal melanoma — a common and difficult-to-treat form of ... Read more

February 22, 2021February 22, 2021

Keytruda-Lenvima Combo Better Than Sutent in Treating Kidney Cancer

News

A combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) worked better than standard Sutent (sunitinib) at delaying disease progression and prolonging survival in adults with untreated advanced renal cell carcinoma (RCC) ... Read more

February 19, 2021February 19, 2021

Opdivo Effective as Bladder Cancer Post-surgery Therapy, Data Show

News

Treatment with Opdivo (nivolumab) after surgery significantly delays disease recurrence or death in patients with muscle-invasive urothelial carcinoma, a form of bladder cancer that has spread to nearby muscles, according ... Read more

February 17, 2021February 17, 2021

FLX475 Shows Promising Safety, Anti-Tumor Activity; Trial Recruiting

News

FLX475, an investigational anti-cancer therapy by RAPT Therapeutics, is safe and shows promising anti-tumor clinical activity, both alone and in combination with Keytruda (pembrolizumab), in certain types of cancer. These ... Read more

February 15, 2021February 15, 2021

Biond and Sanofi Partner, Plan for Trial of Checkpoint Inhibitor BND-22

News

Biond Biologics and Sanofi have entered into a worldwide licensing agreement to advance BND-22, a novel immune checkpoint inhibitor, into clinical testing as a potential treatment of solid tumors. An ... Read more

February 12, 2021February 12, 2021

FDA Approves Libtayo, 1st Immunotherapy for Advanced Basal Cell Carcinoma

News

The U.S. Food and Drug Administration (FDA) has approved Libtayo (cemiplimab-rwlc), making it the first immunotherapy for people with advanced basal cell carcinoma (BCC) — the most common form of ... Read more